Abstract
Міжнародні керівництва не передбачають використання інгібіторів ангіотензинперетворювального ферменту (ІАПФ)/блокаторів рецепторів ангіотензину (БРА) при першій стадії діабетичної хвороби нирок. Наведено погляд, що ґрунтується на нечисленній статистичній вибірці, згідно з яким доцільно використовувати олмесартан (або, можливо, інші ІАПФ/БРА) для профілактики переходу першої стадії діабетичної хвороби нирок у другу при цукровому діабеті 2-го типу.
Highlights
— We recommend not using an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) for the primary prevention of diabetic kidney disease (DKD) in normotensive normoalbuminuric patients with diabetes (1A)
— We suggest using an ACE inhibitor or an ARB in normotensive patients with diabetes and albuminuria levels 30 mg/g who are at high risk of DKD or its progression (2C) [1]
— We suggest that an ARB or ACE inhibitor are used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (2D)
Summary
— We recommend not using an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) for the primary prevention of DKD in normotensive normoalbuminuric patients with diabetes (1A). — We suggest using an ACE inhibitor or an ARB in normotensive patients with diabetes and albuminuria levels 30 mg/g who are at high risk of DKD or its progression (2C) [1]. — We suggest that an ARB or ACE inhibitor are used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) (2D).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
